The results of 2 key studies have been released by OncoMark in relation to the clinical performance of it's OncoMas TR test.
Sigmoid Pharma - now known as Sublimity Therapeutics has closed an enormous $64m round of financing to fund the clinical development of a new drug.
An investment round for ProVerum Medical has recently closed at $4.2m. This investment will help the start-up begin its first human trials for a device to treat benign prostatic hyperplasia (BHP).
Dairy Reporter - Irish company AnaBio Technologies LTD, which specializes in encapsulation using natural food proteins, opened its new facility in Carrigtwohill, near Cork, Ireland recently
Dan MacSweeney has been appointed Chairman to the Board of Directors of Anabio Technologies, his experience and strategic vision is expected to drive the company to become one of the world leaders in micro-encapsulation companies.
Read the article reporting the acquistion of minority interest in the French entity of Venn Life Sciences by the parent company. This will result in Venn Life Sciences plc having full ownership of VLSF.
HBAN (Halo Business Angel Network) plan to sign up 35 new business angel investors at their conference in Dublin on 8th February 2018.
Silicon Republic - Cork medtech firm AventaMed secures €1.8m to take grommets Stateside - Irrus Investments
The Irish Times - Zoetis pays $85m for Irish petcare biopharma Nexvet Please link to the article below by Dominic Coyle which was posted in Apr 2017 by irishtimes.com/business page. Nexvet, the Irish pet pharmaceutical group, had an unusual structure, with the company conducting its drug discovery in Australia, undertaking clinical trials in the United States and Europe, and manufacturing the drugs in Ireland for sale into international markets. The US animal health company, Zoetis has agreed to pay $6.72 per share through Zoetis Bidco, which values Nexvet at $85m. You can access further information by reading the full article [...]
Globe News Wire - Sigmoid Pharma Limited Announces a Strategic Collaboration with Dr. Falk Pharma GmBH Please link to the article below which was posted in Apr 2017 by globenewswire.com. Sigmoid Pharma develop innovative pharmaceuticals for gastrointestinal and immunological diseases, they have entered into an exclusive agreement with Dr. Falk Pharma GmBH advance Sigmoid’s SmPill® cyclosporine franchise in Europe. As part of the agreement Sigmoid are to receive up-front equity investment, development funding as well as clinical and operational support. You can access further information by reading the full article by clicking on the button below. Globe News Wire [...]